Clinical trial
Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's…
NCT00191009 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191009 |
|---|---|
| Title | Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease |
| Official title | Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer's Disease |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | atomoxetine hydrochloride, placebo |
| Enrollment | 124 |
| Start date | Oct 1, 2003 |
| Completion | Jan 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 6, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: